BioTrillion

Excited to share another patent granted to BioTrillion! https://lnkd.in/gVu4N4jh It’s been known for centuries that the eyes are windows into the brain. Valuable signals tied to stress, cognition, and #neurology are hidden in tiny pupil responses that have traditionally been too difficult and expensive to quantify—even during annual medical visits. BioTrillion’s solution is a patented method that uses #computervision to quantify pupillary psychosensory responses, transforming subtle eye behavior into objective, trackable #digitalbiomarkers — directly from a selfie video using a simple smartphone (and other/future devices with cameras). Imagine a future where changes in #brain function can be monitored from a simple smartphone scan—opening the door to more accessible #screening, #remotemonitoring, and improved #outcomes for patients, providers, researchers, and industry partners.

Google expanded Fitbit (now part of Google) with a more personalized AI health coach and medical records integration, bringing consumer tracking and clinical context closer together in one experience. That is a meaningful step toward more connected #DigitalHealth and more useful, context-aware health guidance. BioTrillion has been building toward this same future from a different direction: software-only, smartphone-based biomarker measurement from a 10 second #HealthySelfie. When visual biomarkers, AI, and personal health context converge, #PreventiveHealth becomes more scalable, more accessible, and far more actionable. https://lnkd.in/eJyBy458

WHOOP’s $575 million raise at a $10 billion valuation shows that investors still see major upside in AI-enabled, continuous health monitoring. Platforms that turn everyday behavior into longitudinal health insight continue to attract serious attention in #HealthTech and #AI. BioTrillion sees that same long-term shift through a software-only smartphone lens. While others scale wearables, we are helping push toward a world where a simple 10 second #HealthySelfie can unlock richer biomarker insight, lower friction, and wider access to #PreventiveHealth. https://lnkd.in/erNyDWV6

A new MarketsandMarkets™ / GlobeNewswire release projects the #DigitalBiomarkers market to grow to $15.6B by 2030, driven by AI + wearables + mobile health adoption. BioTrillion is positioned right at the center of that wave: BioEngine4D turns a ~10-second #HealthySelfie into a head-to-toe biomarker set and scales via SDK/API—maximizing completion rates while minimizing environmental noise in the sample. #DigitalHealth #AI #MedTech https://lnkd.in/e5MADTrz

Nature Magazine reports wearables are rapidly reshaping #ClinicalTrials—enabling more real-world, participant-friendly monitoring and accelerating the rise of #DigitalBiomarkers as endpoints. BioTrillion pushes the same trend even further with no new hardware: a ~10-second smartphone scan improves compliance and reduces motion/lighting “taint,” producing cleaner longitudinal baselines for remote endpoints in trials. #Pharma #DCT #HealthAI https://lnkd.in/eUtT2zrF

In February, FDA appointed a new leader for its Digital Health Center of Excellence—underscoring how quickly #AI and software-driven healthcare are moving from “innovation” to “regulated reality.” BioTrillion is building right into that direction: a smartphone-native digital biomarker platform with a clear path toward modular clearances—turning a ~10-second #HealthySelfie into objective “signs” that can scale across payors, providers, and trials. #DigitalHealth #MedTech #HealthAI https://lnkd.in/d9UPr3vM

HLTH Inc. argues we’re at a “digital biomarker inflection point,” where infrastructure—validation science, governance, and regulatory pathways—is finally catching up to the tech. That’s exactly the moment BioTrillion was built for: our ~10-second #HealthySelfie reduces motion/lighting “taint,” boosts repeat usage, and creates cleaner longitudinal baselines—so digital biomarkers can actually work at population scale. #DigitalHealth #AI #RemoteMonitoring #DigitalBiomarkers https://lnkd.in/ebgrWn-C

A new @Nature analysis highlights the growing business case for adopting #digitalendpoints in #ClinicalTrials—because endpoints drive approval, trial economics, and ultimately payer decisions. BioTrillion is purpose-built for this shift: device-free digital biomarkers captured from a ~10-second smartphone scan, enabling higher compliance, cleaner real-world signals, and scalable trial participation—without shipping hardware. #DigitalBiomarkers #HealthAI #Pharma https://lnkd.in/g_E9abCR

In Consumer Healthcare, the highest priorities aren’t just accuracy—it’s also the user experience. Every second with a user is a privilege. HealthySelfie™ is a ~10-second scan—while other camera-based platforms typically ask users to hold still ~30–60 seconds. A shorter scan is a real advantage: * Higher compliance → more people finish the scan, more often * Cleaner data → less motion fatigue + fewer lighting/drift artifacts * More consistent samples → less chance the environment “taints” the video * Better longitudinal baselines → more repeatable check-ins = stronger trend detection * Faster workflows → easier to embed in underwriting, telehealth intake, and trials In digital biomarkers, the best model in the world can’t help if users don’t complete the scan. Imagine when health-checks go from 1x per year to each time you unlock your phone: FaceID => HealthID 🚀 #DigitalHealth #DigitalBiomarkers #HealthAI #LifeInsurance

@Tempus launched @Paige Predict, an AI suite for digital pathology that predicts the likely presence or absence of clinically relevant biomarkers directly from H&E whole slide images, helping clinicians prioritize confirmatory testing when tissue is limited. The announcement notes predictions across many biomarkers and cancer types, aimed at speeding actionable decisions when full molecular profiling is constrained. The common thread with BioTrillion is “make scarce clinical signal more available”: pathology turns slides into biomarkers, and #HealthySelfie turns a smartphone scan into scalable cardio and neuro biomarkers outside the clinic. When biomarker extraction becomes software-defined, recruitment, stratification, and monitoring in #ClinicalTrials gets faster and less site-dependent. #PrecisionMedicine #DigitalBiomarkers #AIinHealthcare https://lnkd.in/e2BpDsmh